Biotics: A Strategic Opportunity to Differentiate in the Immunity Market

Immunity has been a priority for consumers for years, but post-pandemic behaviour has significantly amplified this focus. Global data shows a 20% increase in immune-health product launches in 2021, with a structural CAGR of 8% already in place before COVID-19.

Traditional vitamins and minerals (vitamins D, C, B, zinc) still dominate the category, yet consumers now demand clinically supported, innovative ingredients capable of delivering measurable immune benefits.

This shift is driving strong momentum toward probiotics and prebiotics, which are rapidly becoming high-value differentiators for brands in the nutraceutical and pharmaceutical markets.

Probiotics: High-Growth Alternatives for Immune Support

According to the Council for Responsible Nutrition, 82% of American consumers associate probiotics with immune support—positioning them in the top 10 most recognized immunity ingredients. Market projections confirm this trend, with probiotics expected to grow at 9% CAGR from 2021 to 2028.

Probiotics stand apart thanks to their direct impact on secretory immunoglobulin A (sIgA)—the immune system’s first defensive barrier in the respiratory and intestinal tracts. sIgA levels naturally decrease with age and can be further weakened by stress, medication, lack of sleep, or intense physical activity.

One of the most advanced solutions in this space is Bacillus subtilis CNCM I-2745, known as LifeinU™ BSCU1 from Gnosis by Lesaffre. Clinical studies demonstrate:

• +45% sIgA increase in the respiratory tract
• +87% sIgA increase in the intestinal tract
• 31% reduction in reported infectious episodes
• Average reduction of 2.8 days in common cold duration

These results position LifeinU™ BSCU1 as a strong, premium ingredient for immunity-focused formulations.

Prebiotics: Rising Demand Driven by Microbiome Innovation

The global market for prebiotic-based products is expected to double by 2030, reaching €15 billion. Between 2017 and 2021, the category grew at an impressive 25% CAGR, with 40% of new launches in 2021 positioned in the immune-health segment.

Prebiotics—fibers naturally occurring in plants, grains, fruits, vegetables, and yeasts—stimulate the growth and activity of beneficial bacteria. This fermentation process produces short-chain fatty acids (SCFAs) such as:

• Butyrate & propionate – support immune cell development and differentiation
• Acetate – regulates gut pH and inhibits pathogenic bacteria

Gnosis by Lesaffre introduced Lynside® Immunity Prebiotic, the first yeast-based ingredient patented for its prebiotic effect, validated through advanced in-vitro gut models (PolyFermS®). Studies show:

• SCFA response varies by microbiota profile (enterotype)
• Higher doses of Lynside® Immunity Prebiotic lead to stronger SCFA production, resulting in enhanced immune modulation

Biotics Combinations: The Next Frontier for Immune Health

While probiotics and prebiotics perform strongly on their own, brands increasingly explore symbiotic combinations to benefit from complementary mechanisms:

• LifeinU™ BSCU1 (probiotic): boosts sIgA and first-line immune defense
• Lynside® Immunity Prebiotic: enhances microbiome diversity and SCFA production

This dual approach supports both the immune barrier and the gut ecosystem, offering strong product differentiation and premium positioning opportunities.

The biotics category—encompassing probiotics, prebiotics, and symbiotics—still has vast untapped potential. New applications in supplements and functional foods continue to emerge, giving manufacturers more innovation pathways than ever before.